ID28160A - Sistem pengobatan untuk pemberian fenilasetilglutamina, fenilasetilisoglutamina dan/atau fenilasetat. - Google Patents

Sistem pengobatan untuk pemberian fenilasetilglutamina, fenilasetilisoglutamina dan/atau fenilasetat.

Info

Publication number
ID28160A
ID28160A IDW20010174A ID20010174A ID28160A ID 28160 A ID28160 A ID 28160A ID W20010174 A IDW20010174 A ID W20010174A ID 20010174 A ID20010174 A ID 20010174A ID 28160 A ID28160 A ID 28160A
Authority
ID
Indonesia
Prior art keywords
pharmaceutical composition
phenilasetylisoglutamina
phenilasetylglutamina
phenilasetate
provision
Prior art date
Application number
IDW20010174A
Other languages
English (en)
Indonesian (id)
Inventor
Stanislaw R Burzynski
Original Assignee
Stanislaw R Burzynski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stanislaw R Burzynski filed Critical Stanislaw R Burzynski
Publication of ID28160A publication Critical patent/ID28160A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IDW20010174A 1998-07-23 1999-07-02 Sistem pengobatan untuk pemberian fenilasetilglutamina, fenilasetilisoglutamina dan/atau fenilasetat. ID28160A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/121,567 US6258849B1 (en) 1998-07-23 1998-07-23 Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate

Publications (1)

Publication Number Publication Date
ID28160A true ID28160A (id) 2001-05-10

Family

ID=22397538

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20010174A ID28160A (id) 1998-07-23 1999-07-02 Sistem pengobatan untuk pemberian fenilasetilglutamina, fenilasetilisoglutamina dan/atau fenilasetat.

Country Status (20)

Country Link
US (2) US6258849B1 (OSRAM)
EP (1) EP1098643B1 (OSRAM)
JP (2) JP2002521329A (OSRAM)
KR (4) KR100399658B1 (OSRAM)
CN (3) CN100400039C (OSRAM)
AT (1) ATE257378T1 (OSRAM)
AU (1) AU759278B2 (OSRAM)
BR (1) BR9912356A (OSRAM)
CA (1) CA2336945C (OSRAM)
DE (1) DE69914084T2 (OSRAM)
DK (1) DK1098643T3 (OSRAM)
EA (1) EA004179B1 (OSRAM)
ES (1) ES2214866T3 (OSRAM)
ID (1) ID28160A (OSRAM)
IL (1) IL140848A (OSRAM)
NZ (1) NZ509244A (OSRAM)
PL (1) PL213698B1 (OSRAM)
PT (1) PT1098643E (OSRAM)
WO (1) WO2000004894A2 (OSRAM)
ZA (1) ZA200100622B (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127419A (en) * 1998-11-23 2000-10-03 Burzynski; Stanislaw R. Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis
CA2420576C (en) 2000-08-29 2005-06-14 Nobex Corporation Immunoregulatory compounds, derivatives thereof and their use
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
US20060246016A1 (en) * 2003-05-28 2006-11-02 Burzynski Stanislaw R Toothpaste containing anticancer agents
US7087219B2 (en) * 2003-05-28 2006-08-08 Stanislaw R. Burzynski Toothpaste containing anticancer agents
US7772108B2 (en) * 2004-06-25 2010-08-10 Samsung Electronics Co., Ltd. Interconnection structures for semiconductor devices and methods of forming the same
PL1773767T3 (pl) 2004-07-07 2016-07-29 Biocon Ltd Synteza azowo związanych związków immunoregulacyjnych
JP2008508300A (ja) * 2004-07-28 2008-03-21 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 抗癌剤としての３−ブロモ−２−オキソプロピオン酸プロピルおよび誘導体
WO2006056794A1 (en) * 2004-11-26 2006-06-01 Ucl Business Plc Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy
US20060205818A1 (en) * 2005-03-08 2006-09-14 Burzynski Stanislaw R Method for the treatment of von Hippel-Lindau (VHL) disease with phenylacetyl-derivatives
SMT201700601T1 (it) 2009-04-03 2018-03-08 Ocera Therapeutics Inc L-ornitina fenilacetato e metodi per la sua fabbricazione
EP2799067B1 (en) 2009-06-08 2019-04-03 UCL Business PLC Treatment of brain inflammation using L-Ornithine Phenylacetate
NZ609191A (en) 2010-10-06 2015-06-26 Ocera Therapeutics Inc Methods of making l-ornithine phenyl acetate
KR20230018526A (ko) 2014-11-24 2023-02-07 유씨엘 비즈니스 리미티드 암모니아-저감 치료를 이용한 간성상세포 활성화와 연관된 질병의 치료
HK1249434A1 (zh) 2015-08-18 2018-11-02 Ocera Therapeutics, Inc. 使用与苯乙酸盐和苯丁酸盐中的至少一种组合的l-鸟氨酸治疗和预防肌肉损失
WO2017114686A1 (en) * 2015-12-30 2017-07-06 Nestec S.A. Method for determining fat free body mass
US10624869B2 (en) * 2017-05-08 2020-04-21 Stanislaw R. Burzynski Methods for the treatment of recurrent glioblastoma (RGBM)
IL270413B (en) 2017-05-11 2022-08-01 Ocera Therapeutics Inc Processes of making l-ornithine phenylacetate
IL272422B2 (en) * 2017-06-12 2025-03-01 R Burzynski Stanislaw Methods for the treatment of leptomeningeal disease
US11344521B2 (en) 2017-06-12 2022-05-31 Burzynski Research Institute, Inc. Methods for the treatment of leptomeningeal disease
US20230190694A1 (en) * 2021-11-03 2023-06-22 Stanislaw R. Burzynski Compositions for and methods of precision cancer treatment
CN116019798B (zh) * 2022-07-20 2024-03-12 中南大学湘雅二医院 苯乙酰谷氨酰胺在制备预防和/或治疗阿霉素所致心脏毒性的药物中的应用
CN116491472B (zh) * 2022-12-14 2024-07-26 上海交通大学医学院附属第九人民医院 苯乙酰谷氨酰胺在构建慢性创面动物模型中的用途
WO2024263966A2 (en) * 2023-06-21 2024-12-26 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating pancreatic cancer
WO2024263963A2 (en) * 2023-06-21 2024-12-26 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating head and neck cancer
WO2024263960A2 (en) * 2023-06-21 2024-12-26 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating lung cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284647A (en) 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US4470970A (en) 1981-07-02 1984-09-11 Burzynski Stanislaw R Purified antineoplaston fractions and methods of treating neoplastic disease
US5254587A (en) 1990-09-04 1993-10-19 Burzynski Stanislaw R Methods for treating AIDS
US5244922A (en) 1990-09-04 1993-09-14 Burzynski Stanislaw R Methods for treating viral infections
US5605930A (en) 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
CA2254772C (en) 1996-05-14 2004-01-27 Stanislaw R. Burzynski Liposomal antineoplaston therapies with markedly improved antineoplastic activity

Also Published As

Publication number Publication date
US6258849B1 (en) 2001-07-10
DE69914084T2 (de) 2004-10-28
CN1605334A (zh) 2005-04-13
HK1037142A1 (en) 2002-02-01
ZA200100622B (en) 2002-06-26
EP1098643B1 (en) 2004-01-07
CN1191064C (zh) 2005-03-02
WO2000004894A2 (en) 2000-02-03
NZ509244A (en) 2004-02-27
EA200100168A1 (ru) 2001-08-27
KR20030027088A (ko) 2003-04-03
PT1098643E (pt) 2004-05-31
KR100417100B1 (ko) 2004-02-05
CA2336945C (en) 2008-11-18
KR100414587B1 (ko) 2004-01-13
CN1319010A (zh) 2001-10-24
ES2214866T3 (es) 2004-09-16
BR9912356A (pt) 2001-04-17
JP2002521329A (ja) 2002-07-16
IL140848A0 (en) 2002-02-10
IL140848A (en) 2005-05-17
KR20030027087A (ko) 2003-04-03
DE69914084D1 (de) 2004-02-12
KR100399658B1 (ko) 2003-09-29
KR20010071025A (ko) 2001-07-28
JP2011051993A (ja) 2011-03-17
KR100417101B1 (ko) 2004-02-05
PL213698B1 (pl) 2013-04-30
US6943192B2 (en) 2005-09-13
ATE257378T1 (de) 2004-01-15
AU4854299A (en) 2000-02-14
CA2336945A1 (en) 2000-02-03
WO2000004894A3 (en) 2000-04-27
AU759278B2 (en) 2003-04-10
KR20030027089A (ko) 2003-04-03
EP1098643A2 (en) 2001-05-16
CN100400039C (zh) 2008-07-09
CN1660061A (zh) 2005-08-31
EA004179B1 (ru) 2004-02-26
DK1098643T3 (da) 2004-05-24
US20010044466A1 (en) 2001-11-22
PL345959A1 (en) 2002-01-14

Similar Documents

Publication Publication Date Title
ID28160A (id) Sistem pengobatan untuk pemberian fenilasetilglutamina, fenilasetilisoglutamina dan/atau fenilasetat.
IT1255390B (it) Prodotti farmaceutici per curare malattie tumorali e procedimento per la loro preparazione
ES2137948T3 (es) Sistema avanzado de administracion de medicamentos y metodo de tratamiento de trastornos psiquiatricos, neurologicos y otros con carbamacepina.
ES2130622T3 (es) Sistema para la administracion transdermica de farmacos.
DE69713526D1 (de) Lösliche prodrugs von paclitaxel
DK0913156T3 (da) Anvendelse af aktiveret protein C til behandling af hyperkoagulationstilstande i forbindelse med sepsis
EA200000468A1 (ru) Терапевтическая композиция для введения толтеродина с контролируемым высвобождением
ATE319447T1 (de) Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen
ATE241365T1 (de) Saccharid-enthaltende zubereitungen zur behandlung von alzheimerschen erkrankung und von weiteren amyloidosen
DE69930739D1 (de) Transdermale verwendung von sekretin zur behandlung von autismus
YU54499A (sh) Farmaceutski preparat za primenu na mukozu
DE58901002D1 (de) Mittel mit zerstoerender wirkung auf maligne tumore, verfahren zu dessen herstellung und praeparation zur anwendung in der therapie von krebskranken.
ATE125706T1 (de) Diphosphonate enthaltende pharmazeutische zusammensetzungen zur behandlung von arthrosis.
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
TR200002078T2 (tr) Sentetik polisakkaridler, hazırlanmaları için proses ve bunları içeren farmasötik kompozisyonlar.
BR9708388A (pt) Solução aquosa de hemoglobina polimerizada piridoxilada e processo de sua preparação.
KR960702313A (ko) 티아조푸린 및 리바비린을 사용하는 종양질환의 치료방법 (method for the treatment of neoplastic disease utilizing tlazofurin and ribavirin)
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
DE69630761D1 (de) Verfahren zur verminderung der renalen aufnahme von antikörperfragmenten
GEP20012377B (en) Use of Trophoblastic Beta-1 Glycoprotein for Treating Auto-Immune Diseases and Method of Treatment These Diseases
RU95117518A (ru) Способ лечения аденоидита
SU1744810A1 (ru) Вазоактивное средство, нормализующее функции вегетативной нервной системы "димефосфон"
RO102780B1 (ro) Metoda de anestezie generala
JPS5524150A (en) Anti-malignant-tumor agent
RU97117735A (ru) Способ лечения дифтерии